ANTEOTECH LTD — AGM Information 2016

Nov 13, 2016

==> picture [720 x 126] intentionally omitted <==

==> picture [99 x 98] intentionally omitted <==

==> picture [98 x 98] intentionally omitted <==

==> picture [98 x 98] intentionally omitted <==

==> picture [98 x 98] intentionally omitted <==

Anteo Diagnostics Limited (ASX:ADO) Annual General Meeting 2016

==> picture [98 x 98] intentionally omitted <==

==> picture [99 x 98] intentionally omitted <==

==> picture [98 x 98] intentionally omitted <==

==> picture [98 x 98] intentionally omitted <==

==> picture [146 x 74] intentionally omitted <==

==> picture [147 x 74] intentionally omitted <==

==> picture [147 x 74] intentionally omitted <==

==> picture [50 x 74] intentionally omitted <==

==> picture [720 x 149] intentionally omitted <==

==> picture [720 x 54] intentionally omitted <==

Meeting Format

1. Chairman’s Welcome

2. Formal Resolutions

3. Group CEO Report

4. Other Business

5. Meeting Close.

==> picture [283 x 239] intentionally omitted <==

TEM image shows ~2 nm thick Mix&Go polymer films on 40 nm gold nanoparticles

2

==> picture [720 x 54] intentionally omitted <==

Directors and Management in Attendance

==> picture [104 x 104] intentionally omitted <==

==> picture [102 x 104] intentionally omitted <==

==> picture [94 x 106] intentionally omitted <==

==> picture [90 x 106] intentionally omitted <==

Dr John Hurrell Non-executive Director

Dr Geoff Cumming Non-executive Director

Mr Rolf Sickman Mr Richard Martin Non-executive Non-executive Director Director

==> picture [77 x 92] intentionally omitted <==

Dr Jef Vangenechten Group CEO

==> picture [93 x 93] intentionally omitted <==

Mr Peter Harding-Smith Group CFO & Company Secretary

==> picture [62 x 92] intentionally omitted <==

Ms Tamara Mills COO – Australian Operations

3

==> picture [720 x 54] intentionally omitted <==

Formal Resolutions

Resolution		Description
1		Adoption of Directors’ Remuneration Report
2		Re-election of Director (Mr Rolf Sickman)
3		Re-election of Director (Dr Geoff Cumming)
4		Re-election of Director (Mr Mark Bouris)
5		Re-election of Director (Dr John Hurrell)
6		Approval of 10% Placement Facility
7		Ratification of Share Issue

4

==> picture [720 x 54] intentionally omitted <==

Resolution Proxy Count

Res		Description	For	Against	Open	Excluded	Abstain	Totals
1		Adoption of Directors’ Remuneration Report	248,024,387	79,096,799	15,395,282	45,802,884	11,388,480	399,707,832
2		Re-election of Director (Mr Rolf Sickman)	344,465,570	31,824,002	13,447,837	4,664,800	5,305,623	399,707,832
3		Re-election of Director (Dr Geoff Cumming)	318,180,664	40,452,253	18,072,637	22,833,333	168,945	399,707,832
4		Re-election of Director (Mr Mark Bouris)	Resolution withdrawn
5		Re-election of Director (Dr John Hurrell)	280,300,827	84,256,275	19,042,637	0	16,108,093	399,707,832
6		Approval of 10% Placement Facility	246,197,574	134,358,400	18,015,589	0	1,136,269	399,707,832
7		Ratification of Share Issue	229,898,551	79,543,898	18,735,262	68,015,482	3,514,639	399,707,832

5

Group CEO Update

1. New Executive team 2. Anteo: a true platform technology 3. Group vision 4. Diagnostics 5. Medical Devices

2. Energy

3. Conclusions

6

New Executive Team

==> picture [76 x 92] intentionally omitted <==

Dr Jef Vangenechten Group CEO

• Appointed June 2016

• Extensive business experience

• In-depth Diagnostic Industry knowledge

• Ph.D.

• Biology/Physiology

==> picture [61 x 92] intentionally omitted <==

Ms Tamara Mills COO Australian Operations

• Appointed August 2016

• Extensive

• commercialisation

• experience

• Medical Device Background

==> picture [93 x 94] intentionally omitted <==

Mr Peter Harding-Smith Group CFO Company Secretary

• ₋ Appointed October

2016

• ₋ Chartered Accountant

• ASX and capital market experience

• ₋

7

A True Platform Technology

==> picture [320 x 304] intentionally omitted <==

----- Start of picture text -----

Anteo
Group
----- End of picture text -----

Anteo Nano-chemistry technology has applications in a number of different industries

8

Current Focus

1. Diagnostics and life sciences : effectively binding antibodies, antigens and other biological proteins to surfaces and beads (particles)

2. Medical Devices : to bond the nylon surface of sheaths and the lubricious hydrophilic coating.

3. Energy : Si anodes in Li-ion batteries : to prevent Si anodes from disintegrate because of swelling and shrinking during load/unload cycles.

9

Group Vision

sales and operational cash flows operational maturity

Assay Development

DIAsource Platform ISO Manufacturing Commercialisation & BD

10

Group Vision

Diagnostic markets:

• PoC Development

• • Products

Anteo Technologies

Medical Devices

Energy

11

Group Vision

==> picture [602 x 360] intentionally omitted <==

----- Start of picture text -----

PoC Development
DIAsource Anteo
Platform Manufacturing Technologies
Medical Devices
Commercialisation
Energy
----- End of picture text -----

12

Diagnostics and Life sciences

o Core strengths

• Applying our technology at the smallest scale possible

• Point of Care space

o Executing on multiple partnering opportunities: Commercial value beginning to follow through

==> picture [87 x 42] intentionally omitted <==

==> picture [61 x 42] intentionally omitted <==

==> picture [114 x 17] intentionally omitted <==

o Anteo and DIAsource are working together within the PoC space

==> picture [161 x 242] intentionally omitted <==

TEM images of Quantum Dots (10 nm) bound to Mix&Go activated magnetic nanoparticles (200 nm)

13

Diagnostic Revenue Sources

==> picture [720 x 425] intentionally omitted <==

----- Start of picture text -----

Professional
Product Sales
Services
Direct
R&D
Distribution
Custom Custom
formulation Manufacturing
Royalties
Product Life Cycle
----- End of picture text -----

14

Financial strength DIAsource

o From 2014 to 2016 the yearly revenue grew from 11.8m € to over 15m € o EBITDA increased from 10% to approaching 20% of revenue

Sales by Quarter - Q1 2014 to Q3 2016

==> picture [541 x 279] intentionally omitted <==

----- Start of picture text -----

4,500,000
4,000,000
3,500,000
3,000,000
2,500,000
2,000,000
2014-Q1 2014-Q2 2014-Q3 2014-Q4 2015-Q1 2015-Q2 2015-Q3 2015-Q4 2016-Q1 2016-Q2 2016-Q3
----- End of picture text -----

• € 4,500,000

==> picture [720 x 57] intentionally omitted <==

Business Organization DIAsource

==> picture [276 x 246] intentionally omitted <==

----- Start of picture text -----

ELISA
Vitamin D RIA
& Other
Latin countries
FraBeLux
Product Specialists
Marketing
----- End of picture text -----

16

Future Business Organization DIAsource

Synergy for commercialization and business development

==> picture [378 x 246] intentionally omitted <==

----- Start of picture text -----

Assay
ELISA Components
Vitamin D RIA
& Other Anteo
Products
Direct
Latin countries
contacts
FraBeLux Distributors
Product Specialists
Marketing
----- End of picture text -----

17

Group Vision

Business Development

DIAsource Platform

Anteo Technologies ISO Manufacturing Medical Devices Energy

18

Anteo –– Medical Device

Our goal:

To collaborate with Medical Device partners to achieve better and safer outcomes for patients through innovative surface modification.

==> picture [94 x 94] intentionally omitted <==

Multiple ongoing development collaborations with Cook Medical

==> picture [94 x 72] intentionally omitted <==

Actively strengthening Anteo’s IP position in the medical device space:

• Conductive fibres provisional filed October

• Core to applications within active implantable devices

19

Group Vision

DIAsource Platform

Anteo Technologies Manufacturing Medical Devices Energy

20

Anteo Energy

• Anteo coating provides strong bonds between silicon and binder which enhances structural integrity.

• Proof of principle data shows

  • Increased energy capacity

  • Increased battery life

• Simple drop-in technology to existing Liion battery manufacturing

• Key industry players showed, have indicated strong interest in our technology

==> picture [209 x 168] intentionally omitted <==

----- Start of picture text -----

Without Anteo technology
----- End of picture text -----

Example of SEM images of electrodes after >500 deep charge/discharge cycles.

==> picture [214 x 172] intentionally omitted <==

----- Start of picture text -----

With Anteo technology
----- End of picture text -----

21

Anteo Energy

• Partner with expert Li-ion RnD partner to accelerate industry standard data package generation

• Intention of entering commercial development arrangements with one or more of the following organizations.

==> picture [121 x 122] intentionally omitted <==

==> picture [250 x 83] intentionally omitted <==

==> picture [178 x 42] intentionally omitted <==

==> picture [127 x 35] intentionally omitted <==

==> picture [391 x 40] intentionally omitted <==

22

Conclusion

• Current capabilities:

• Greater acceptance of Anteo’s technology in the Diagnostic market

• Increase financial strength with the acquisition of DIAsource

• Deeper Commercial experience with the DIAsource and new Senior management team

• This will lead to:

• Greater emphasis on commercialisation and underlying profitability

• Increase focus on IP generation, combined with a solid IP strategy

• Long term value creation

• A shift from the exploring the technology to exploiting the technology

23

23

==> picture [720 x 54] intentionally omitted <==

Thank you for your time, your interest and your continued support

==> picture [415 x 85] intentionally omitted <==

24